- Home
- PMVP vs IMRX Comparison
PMVP vs IMRX Comparison
Compare PMVP & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- IMRX
- Stock Information
- Founded
- PMVP 2013
- IMRX 2008
- Country
- PMVP United States
- IMRX United States
- Employees
- PMVP N/A
- IMRX N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- IMRX Health Care
- Exchange
- PMVP Nasdaq
- IMRX Nasdaq
- Market Cap
- PMVP 55.1M
- IMRX 68.4M
- IPO Year
- PMVP 2020
- IMRX 2021
- Fundamental
- Price
- PMVP $1.20
- IMRX $3.45
- Analyst Decision
- PMVP Strong Buy
- IMRX Strong Buy
- Analyst Count
- PMVP 1
- IMRX 4
- Target Price
- PMVP $5.00
- IMRX $13.25
- AVG Volume (30 Days)
- PMVP 278.5K
- IMRX 2.9M
- Earning Date
- PMVP 08-07-2025
- IMRX 08-05-2025
- Dividend Yield
- PMVP N/A
- IMRX N/A
- EPS Growth
- PMVP N/A
- IMRX N/A
- EPS
- PMVP N/A
- IMRX N/A
- Revenue
- PMVP N/A
- IMRX N/A
- Revenue This Year
- PMVP N/A
- IMRX N/A
- Revenue Next Year
- PMVP N/A
- IMRX N/A
- P/E Ratio
- PMVP N/A
- IMRX N/A
- Revenue Growth
- PMVP N/A
- IMRX N/A
- 52 Week Low
- PMVP $0.81
- IMRX $1.00
- 52 Week High
- PMVP $1.82
- IMRX $3.87
- Technical
- Relative Strength Index (RSI)
- PMVP 57.96
- IMRX 67.77
- Support Level
- PMVP $0.96
- IMRX $2.29
- Resistance Level
- PMVP $1.14
- IMRX $3.87
- Average True Range (ATR)
- PMVP 0.07
- IMRX 0.47
- MACD
- PMVP -0.00
- IMRX 0.08
- Stochastic Oscillator
- PMVP 65.28
- IMRX 80.89
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.